Delphine Rea (Delphine Réa)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 37

Top Venues

Leukemia

British journal of haematology

Blood

Current hematologic malignancy reports

Université Paris VI (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Université Paris VI

France

PHD

Publications

Elias J Jabbour, Jane F Apperley, Jorge E Cortes, Delphine Rea, Michael W Deininger, Elisabetta Abruzzese, Charles Chuah, Daniel J DeAngelo, Andreas Hochhaus, Jeffrey H Lipton, Michael J Mauro, Franck Nicolini, Javier Pinilla-Ibarz, Gianantonio Rosti, Philippe Rousselot, Neil P Shah, Moshe Talpaz, Alexander Vorog, Xiaowei Ren, Hagop M Kantarjian
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia (2024)
Elias J Jabbour, Jane F Apperley, Jorge E Cortes, Delphine Rea, Michael W Deininger, Elisabetta Abruzzese, Charles Chuah, Daniel J DeAngelo, Andreas Hochhaus, Jeffrey H Lipton, Michael J Mauro, Franck Nicolini, Javier Pinilla-Ibarz, Gianantonio Rosti, Philippe Rousselot, Neil P Shah, Moshe Talpaz, Alexander Vorog, Xiaowei Ren, Hagop M Kantarjian
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia 38 (3) (2024)
Delphine Rea, Sofiane Fodil, Etienne Lengline, Emmanuel Raffoux, Jean-Michel Cayuela
Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Strategies to Optimize Success and New Directions. Current hematologic malignancy reports 19 (3) (2024)
Francois-Xavier Mahon, Markus Pfirrmann, Stephanie Dulucq, Andreas Hochhaus, Panayiotis Panayiotidis, Antonio Almeida, Jiří Mayer, Henrik Hjorth-Hansen, Jeroen J W M Janssen, Mohamed El Missiry, Joaquin Martinez Lopez, Hanne Vestergaard, Hans Ehrencrona, Katerina Machová Poláková, Ulla Olsson-Strömberg, Gert Ossenkoppele, Marc G Berger, Gabriel Etienne, Jolanta Dengler, Tim Henrik Brümmendorf, Andreas Burchert, Delphine Rea, Philippe Rousselot, Franck E Nicolini, Wolf-Karsten Hofmann, Johan Richter, Susanne Saussele, null null, null null
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (16) (2024)
Delphine Rea, Sofiane Fodil, Etienne Lengline, Emmanuel Raffoux, Jean-Michel Cayuela
Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Strategies to Optimize Success and New Directions. Current hematologic malignancy reports (2024)
Ariel Leyte-Vidal, Diego Garrido Ruiz, RosaAnna DeFilippis, Inga B Leske, Delphine Rea, Stacey Phan, Kaeli B Miller, Feifei Hu, Anjeli Mase, Yibing Shan, Oliver Hantschel, Matthew P Jacobson, Neil P Shah
BCR::ABL1 Kinase N-lobe Mutants Confer Moderate to High Degrees of Resistance to Asciminib. Blood (2024)
Vincent Alcazer, Stéphane Morisset, Delphine Rea, Laurence Legros, Stephanie Dulucq, Sandrine Hayette, Jean-Michel Cayuela, Françoise Huguet, François-Xavier Mahon, Gabriel Etienne, Franck Emmanuel Nicolini
Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients. British journal of haematology 204 (4) (2024)
Vincent Alcazer, Stéphane Morisset, Delphine Rea, Laurence Legros, Stephanie Dulucq, Sandrine Hayette, Jean-Michel Cayuela, Françoise Huguet, François-Xavier Mahon, Gabriel Etienne, Franck Emmanuel Nicolini
Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients. British journal of haematology (2024)
Ariel Leyte-Vidal, RosaAnna DeFilippis, Ian R Outhwaite, Isabelle Kwan, Ji Young Lee, Carlyn Leavitt, Kaeli B Miller, Delphine Rea, Aziz M Rangwala, Kevin Lou, Suhana Patel, Ailin Alvarez, Kevan M Shokat, Ivet Bahar, Markus A Seeliger, Neil P Shah
Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib. Leukemia (2024)
Ariel Leyte-Vidal, RosaAnna DeFilippis, Ian R Outhwaite, Isabelle Kwan, Ji Young Lee, Carlyn Leavitt, Kaeli B Miller, Delphine Rea, Aziz M Rangwala, Kevin Lou, Suhana Patel, Ailin Alvarez, Kevan M Shokat, Ivet Bahar, Markus A Seeliger, Neil P Shah
Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib. Leukemia 38 (9) (2024)
Elias J Jabbour, Jane F Apperley, Jorge E Cortes, Delphine Rea, Michael W Deininger, Elisabetta Abruzzese, Charles Chuah, Daniel J DeAngelo, Andreas Hochhaus, Jeffrey H Lipton, Michael J Mauro, Franck Nicolini, Javier Pinilla-Ibarz, Gianantonio Rosti, Philippe Rousselot, Neil P Shah, Moshe Talpaz, Alexander Vorog, Xiaowei Ren, Hagop M Kantarjian
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia 38 (3) (2024)
Ariel Leyte-Vidal, Diego Garrido Ruiz, RosaAnna DeFilippis, Inga B Leske, Delphine Rea, Stacey Phan, Kaeli B Miller, Feifei Hu, Anjeli Mase, Yibing Shan, Oliver Hantschel, Matthew P Jacobson, Neil P Shah
BCR::ABL1 Kinase N-lobe Mutants Confer Moderate to High Degrees of Resistance to Asciminib. Blood (2024)
Elias J Jabbour, Jane F Apperley, Jorge E Cortes, Delphine Rea, Michael W Deininger, Elisabetta Abruzzese, Charles Chuah, Daniel J DeAngelo, Andreas Hochhaus, Jeffrey H Lipton, Michael J Mauro, Franck Nicolini, Javier Pinilla-Ibarz, Gianantonio Rosti, Philippe Rousselot, Neil P Shah, Moshe Talpaz, Alexander Vorog, Xiaowei Ren, Hagop M Kantarjian
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia 38 (3) (2024)
Delphine Rea, Sofiane Fodil, Etienne Lengline, Emmanuel Raffoux, Jean-Michel Cayuela
Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Strategies to Optimize Success and New Directions. Current hematologic malignancy reports 19 (3) (2024)
Elias J Jabbour, Jane F Apperley, Jorge E Cortes, Delphine Rea, Michael W Deininger, Elisabetta Abruzzese, Charles Chuah, Daniel J DeAngelo, Andreas Hochhaus, Jeffrey H Lipton, Michael J Mauro, Franck Nicolini, Javier Pinilla-Ibarz, Gianantonio Rosti, Philippe Rousselot, Neil P Shah, Moshe Talpaz, Alexander Vorog, Xiaowei Ren, Hagop M Kantarjian
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia 38 (3) (2024)
Francois-Xavier Mahon, Markus Pfirrmann, Stephanie Dulucq, Andreas Hochhaus, Panayiotis Panayiotidis, Antonio Almeida, Jiří Mayer, Henrik Hjorth-Hansen, Jeroen J W M Janssen, Mohamed El Missiry, Joaquin Martinez Lopez, Hanne Vestergaard, Hans Ehrencrona, Katerina Machová Poláková, Ulla Olsson-Strömberg, Gert Ossenkoppele, Marc G Berger, Gabriel Etienne, Jolanta Dengler, Tim Henrik Brümmendorf, Andreas Burchert, Delphine Rea, Philippe Rousselot, Franck E Nicolini, Wolf-Karsten Hofmann, Johan Richter, Susanne Saussele, null null
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Elias J Jabbour, Jane F Apperley, Jorge E Cortes, Delphine Rea, Michael W Deininger, Elisabetta Abruzzese, Charles Chuah, Daniel J DeAngelo, Andreas Hochhaus, Jeffrey H Lipton, Michael J Mauro, Franck Nicolini, Javier Pinilla-Ibarz, Gianantonio Rosti, Philippe Rousselot, Neil P Shah, Moshe Talpaz, Alexander Vorog, Xiaowei Ren, Hagop M Kantarjian
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia 38 (3) (2024)
Elias J Jabbour, Jane F Apperley, Jorge E Cortes, Delphine Rea, Michael W Deininger, Elisabetta Abruzzese, Charles Chuah, Daniel J DeAngelo, Andreas Hochhaus, Jeffrey H Lipton, Michael J Mauro, Franck Nicolini, Javier Pinilla-Ibarz, Gianantonio Rosti, Philippe Rousselot, Neil P Shah, Moshe Talpaz, Alexander Vorog, Xiaowei Ren, Hagop M Kantarjian
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia 38 (3) (2024)
Ariel Leyte-Vidal, RosaAnna DeFilippis, Ian R Outhwaite, Isabelle Kwan, Ji Young Lee, Carlyn Leavitt, Kaeli B Miller, Delphine Rea, Aziz M Rangwala, Kevin Lou, Suhana Patel, Ailin Alvarez, Kevan M Shokat, Ivet Bahar, Markus A Seeliger, Neil P Shah
Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib. Leukemia 38 (9) (2024)
Delphine Rea, Sofiane Fodil, Etienne Lengline, Emmanuel Raffoux, Jean-Michel Cayuela
Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Strategies to Optimize Success and New Directions. Current hematologic malignancy reports 19 (3) (2024)
Elias J Jabbour, Jane F Apperley, Jorge E Cortes, Delphine Rea, Michael W Deininger, Elisabetta Abruzzese, Charles Chuah, Daniel J DeAngelo, Andreas Hochhaus, Jeffrey H Lipton, Michael J Mauro, Franck Nicolini, Javier Pinilla-Ibarz, Gianantonio Rosti, Philippe Rousselot, Neil P Shah, Moshe Talpaz, Alexander Vorog, Xiaowei Ren, Hagop M Kantarjian
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia 38 (3) (2024)
Elias J Jabbour, Jane F Apperley, Jorge E Cortes, Delphine Rea, Michael W Deininger, Elisabetta Abruzzese, Charles Chuah, Daniel J DeAngelo, Andreas Hochhaus, Jeffrey H Lipton, Michael J Mauro, Franck Nicolini, Javier Pinilla-Ibarz, Gianantonio Rosti, Philippe Rousselot, Neil P Shah, Moshe Talpaz, Alexander Vorog, Xiaowei Ren, Hagop M Kantarjian
Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia (2024)
Ariel Leyte-Vidal, RosaAnna DeFilippis, Ian R Outhwaite, Isabelle Kwan, Ji Young Lee, Carlyn Leavitt, Kaeli B Miller, Delphine Rea, Aziz M Rangwala, Kevin Lou, Suhana Patel, Ailin Alvarez, Kevan M Shokat, Ivet Bahar, Markus A Seeliger, Neil P Shah
Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib. Leukemia 38 (9) (2024)
Ariel Leyte-Vidal, RosaAnna DeFilippis, Ian R Outhwaite, Isabelle Kwan, Ji Young Lee, Carlyn Leavitt, Kaeli B Miller, Delphine Rea, Aziz M Rangwala, Kevin Lou, Suhana Patel, Ailin Alvarez, Kevan M Shokat, Ivet Bahar, Markus A Seeliger, Neil P Shah
Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib. Leukemia 38 (9) (2024)
Ariel Leyte-Vidal, Diego Garrido Ruiz, RosaAnna DeFilippis, Inga B Leske, Delphine Rea, Stacey Phan, Kaeli B Miller, Feifei Hu, Anjeli Mase, Yibing Shan, Oliver Hantschel, Matthew P Jacobson, Neil P Shah
BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib. Blood 144 (6) (2024)
Vincent Alcazer, Stéphane Morisset, Delphine Rea, Laurence Legros, Stephanie Dulucq, Sandrine Hayette, Jean-Michel Cayuela, Françoise Huguet, François-Xavier Mahon, Gabriel Etienne, Franck Emmanuel Nicolini
Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients. British journal of haematology 204 (4) (2024)
Delphine Rea, Carla Boquimpani, Michael J Mauro, Yosuke Minami, Alex Allepuz, Vikalp Kumar Maheshwari, Denise D'Alessio, Ying Wu, Rachael Lawrance, Sarunas Narbutas, Giora Sharf, Andreas Hochhaus
Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial. Leukemia (2023)
Stephanie Dulucq, Françoise Rigal-Huguet, Franck Emmanuel Nicolini, Pascale Cony-Makhoul, Martine Escoffre-Barbe, Martine Gardembas, Laurence Legros, Philippe Rousselot, Jixing Liu, Delphine Rea, Véronique De Mas, Sandrine Hayette, Sophie Raynaud, Caroline Lacoste-Roussillon, Fanny Robbesyn, Emilie Klein, Stéphane Morisset, François-Xavier Mahon, Gabriel Etienne
Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study. British journal of haematology (2023)
Neil P Shah, Valentín García-Gutiérrez, Antonio Jiménez-Velasco, Sarah M Larson, Susanne Saussele, Delphine Rea, François-Xavier Mahon, Moshe Yair Levy, María Teresa Gómez-Casares, Michael J Mauro, Oumar Sy, Patricia Martin-Regueira, Jeffrey H Lipton
Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE. British journal of haematology (2023)
Lydia Roy, Jean-Claude Chomel, Joëlle Guilhot, Agnès Guerci-Bresler, Martine Escoffre-Barbe, Stéphane Giraudier, Aude Charbonnier, Viviane Dubruille, Françoise Huguet, Hyacinthe Johnson-Ansah, Pascal Lenain, Shanti Ame, Gabriel Etienne, Franck Emmanuel Nicolini, Delphine Rea, Pascale Cony-Makhoul, Stéphane Courby, Jean-Christophe Ianotto, Laurence Legros, Antoine Machet, Valérie Coiteux, Eric Hermet, Emilie Cayssials, Stéphane Bouchet, Francois-Xavier Mahon, Philippe Rousselot, François Guilhot, null null
Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study). British journal of haematology (2022)
Delphine Rea, Michael J Mauro, Carla Boquimpani, Yosuke Minami, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong-Wook Kim, Jane F Apperley, Andre Neder Ramires Abdo, Laura Maria Fogliatto, Dennis Dong Hwan Kim, Philipp le Coutre, Susanne Saussele, Mario Annunziata, Timothy P Hughes, Naeem Chaudhri, Koiji Sasaki, Lynette Chee, J Valentín García-Gutiérrez, Jorge E Cortes, Paola Aimone, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Andreas Hochhaus
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood 138 (21) (2021)
Philippe Rousselot, Luigina Mollica, Joëlle Guilhot, Agnès Guerci, Franck E Nicolini, Gabriel Etienne, Laurence Legros, Aude Charbonnier, Valérie Coiteux, Caroline Dartigeas, Martine Escoffre-Barbe, Lydia Roy, Pascale Cony-Makhoul, Viviane Dubruille, Martine Gardembas, Françoise Huguet, Delphine Rea, Emilie Cayssials, François Guilhot, Anne Bergeron, Mathieu Molimard, Francois-Xavier Mahon, Jean-Michel Cayuela, Lambert Busque, Stéphane Bouchet
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients. British journal of haematology 194 (2) (2021)
Clémence Marcault, Lin-Pierre Zhao, Nabih Maslah, Emmanuelle Verger, Rafael Daltro de Oliveira, Juliette Soret-Dulphy, Marine Cazaux, Nicolas Gauthier, Blandine Roux, Emmanuelle Clappier, Nathalie Parquet, Christine Dosquet, Delphine Rea, Jean-Marc Zini, William Vainchenker, Emmanuel Raffoux, Stéphane Giraudier, Jean-Jacques Kiladjian, Bruno Cassinat, Lina Benajiba
Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms. Blood 138 (21) (2021)
Marc G Berger, Bruno Pereira, Philippe Rousselot, Pascale Cony-Makhoul, Martine Gardembas, Laurence Legros, Martine Escoffre-Barbe, Franck-Emmanuel Nicolini, Sandrine Saugues, Céline Lambert, Delphine Rea, Agnès Guerci-Bresler, Stéphane Giraudier, Joëlle Guilhot, Susanne Saussele, François-Xavier Mahon, null null
Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome. British journal of haematology 187 (3) (2019)
Pierre-Yves Dumas, Emilie Bérard, Claire Bréal, Stéphanie Dulucq, Delphine Rea, Franck Nicolini, Edouard Forcade, Melody Dufossée, Jean-Max Pasquet, Béatrice Turcq, Audrey Bidet, Noel Milpied, Julie Déchanet-Merville, Xavier Lafarge, Gabriel Etienne, François-Xavier Mahon, null null
Killer immunoglobulin-like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment-free remission. Cancer medicine 8 (11) (2019)
Delphine Rea, Shanti Ame, Marc Berger, Jean-Michel Cayuela, Aude Charbonnier, Valérie Coiteux, Pascale Cony-Makhoul, Viviane Dubruille, Stéphanie Dulucq, Gabriel Etienne, Laurence Legros, Franck Nicolini, Catherine Roche-Lestienne, Martine Escoffre-Barbe, Martine Gardembas, Agnès Guerci-Bresler, Hyacinthe Johnson-Ansah, Françoise Rigal-Huguet, Philippe Rousselot, François-Xavier Mahon, null null
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group. Cancer 124 (14) (2018)
Delphine Rea, François-Xavier Mahon
How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy. British journal of haematology 180 (1) (2017)

Delphine Rea.css-eqlu8i{font-size:small;padding-left:4px;} (Delphine Réa)

Publication Activity (10 Years)

Top Topics

Top Venues

Delphine Rea (Delphine Réa)